Nanosecond-pulsed plasma jet in air and air/helium mixtures: Plasma properties and anticancer effect

Nanosecond-pulse power has the characteristics of quickly increasing applied power, short pulse width, and considerably high-energy electrons. In this study, we investigated the different air/helium mixture ratios of nanosecond-pulsed-power-driven plasma jet discharge characteristics and the physico...

Full description

Saved in:
Bibliographic Details
Published in:Physics of plasmas 2023-03, Vol.30 (3)
Main Authors: Qi, Miao, Zhang, Xinying, Peng, Sansan, Fan, Runze, Pang, Bolun, Luo, Rong, Ding, Zhenjie, Xu, Dehui, Liu, Dingxin
Format: Article
Language:English
Subjects:
Anticancer properties
Apoptosis
Chemotherapy
Fourier transforms
Helium
High energy electrons
Hydrogen peroxide
Infrared spectroscopy
Mixtures
Nanosecond pulses
Plasma jets
Plasma physics
Pulse duration
Short pulses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanosecond-pulse power has the characteristics of quickly increasing applied power, short pulse width, and considerably high-energy electrons. In this study, we investigated the different air/helium mixture ratios of nanosecond-pulsed-power-driven plasma jet discharge characteristics and the physicochemical properties of the gaseous and aqueous phases. Results showed that the length and luminescence intensity of the plasma increased with decreasing air ratio. Notably, there is a maximum inflection point in N2O5 of Fourier transform infrared spectrometry detection and concentration of H2O2 at 70% air ratio. Furthermore, we used drug-resistant ovarian cancer cells (A2780/ADR) as a model to detect the anticancer effect, with the results indicating that 70% air ratio is the best condition to inhibit cell growth and induce cell apoptosis. Our research indicates that the air discharge driven by a nanosecond-pulse power supply has potential application in an ovarian cancer drug-resistant tumor cell therapy.
ISSN:1070-664X
1089-7674
DOI:10.1063/5.0136765